Bank CEOs meet with Trump to discuss Fannie Mae and Freddie Mac - Bloomberg
Tivic Health Systems , Inc. (NASDAQ:TIVC), currently trading at $4.45 with a market capitalization of $2.66 million, has announced that its 2025 Annual Meeting of Stockholders will be held virtually on June 30, 2025. The record date for determining stockholders entitled to vote at the meeting is set for May 14, 2025, with the company reserving the right to change the date and/or record date if necessary. According to InvestingPro data, the stock has experienced significant volatility, with a year-to-date return of -27.11%.
The company has also indicated that the deadline for stockholder proposals for the Annual Meeting has been revised. Proposals submitted pursuant to Rule 14a-8 for inclusion in the proxy statement must be received by Tivic Health by May 26, 2025. This deadline allows the company reasonable time before it begins printing and mailing its proxy materials. Stockholders must adhere to Rule 14a-8 requirements and submit their proposals no later than the stated date. InvestingPro analysis reveals that while the company maintains a healthy current ratio of 1.7, its overall financial health score is categorized as WEAK, making stockholder engagement particularly crucial.
In addition, stockholders intending to present director nominations or other business at the Annual Meeting, not in accordance with Rule 14a-8, must ensure their submissions comply with the Exchange Act and the company’s Amended and Restated Bylaws, and are received by May 26, 2025.
Furthermore, stockholders planning to solicit proxies in support of director nominees other than those nominated by the company must provide notice as required by Rule 14a-19 under the Exchange Act by May 30, 2025, which is ten days following the Current Report on Form 8-K announcing the Annual Meeting date.
The information contained in this article is based on Tivic Health Systems, Inc.’s recent SEC filing. For comprehensive analysis and additional insights, including 12 more exclusive ProTips and detailed financial metrics, visit InvestingPro, where you can access the full Pro Research Report for TIVC.
In other recent news, Tivic Health Systems Inc. reported a substantial decrease in revenue for the first quarter of 2025, with sales dropping 79% from the previous year to $70,000. Despite the revenue decline, the company improved its gross margins significantly, from 50% to 72%, by reducing advertising expenses by 92%. Tivic Health is undergoing a strategic shift towards a diversified focus in immunotherapeutics, marked by acquiring rights to the drug candidate Entelimod. The company remains optimistic about its future, projecting revenues of $8.03 million and $14.06 million for fiscal years 2025 and 2026, respectively. Additionally, Tivic Health has entered into an $8.4 million strategic financing agreement to support its transformation. The company secured a $25 million equity line of credit, with the first drawdown expected in the second quarter. Analysts and investors are closely monitoring Tivic Health’s strategic shift and financial performance as it transitions into a diversified immunotherapeutics entity.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.